Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT04434937 Completed - Lymphoma Clinical Trials

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

Start date: September 30, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of parsaclisib in Japanese participants with relapsed or refractory follicular lymphoma

NCT ID: NCT04434833 Recruiting - Clinical trials for Non Hodgkin Lymphoma

A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma

Start date: July 1, 2020
Phase:
Study type: Observational

Using single-cell RNA sequencing, this study will explore the heterogeneity of lymphoma inside and outside the lymph node, identify tumor specific molecular markers and cell subgroups, explore the differences in tumor microenvironment composition, and provide a basis for diagnosis and precision treatment.

NCT ID: NCT04434196 Active, not recruiting - Clinical trials for Lymphoma, Non-Hodgkin

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start date: December 21, 2020
Phase: Phase 1
Study type: Interventional

CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

NCT ID: NCT04433182 Active, not recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Start date: August 18, 2020
Phase: Phase 2
Study type: Interventional

This is a multicentric single arm phase II trial, to investigate the efficacy (in terms of PFS) of the combination regimen rituximab-bendamustine in association with copanlisib in patients affected by relapsed/refractory DLBCL, not eligible to HDC and ASCT or relapsed after intensified regimens.

NCT ID: NCT04433156 Recruiting - Clinical trials for Marginal Zone Lymphoma

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Start date: April 22, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

NCT ID: NCT04432506 Completed - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Start date: July 27, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and best dose of anakinra and to see how well it works in reducing side effects (toxicity) associated with a CAR-T cell treatment called axicabtagene ciloleucel in patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refractory). Anakinra is a drug typically used to treat rheumatoid arthritis but may also help in reducing CAR-T cell therapy toxicity. Giving anakinra in combination with axicabtagene ciloleucel may help control relapsed or refractory large B-cell lymphoma.

NCT ID: NCT04432402 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Start date: June 14, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate efficacy and safety of Lenalidomide in combination with R-GemOx as first-line treatment of elderly patients with Diffuse large B cell lymphoma.

NCT ID: NCT04431635 Active, not recruiting - Indolent Lymphoma Clinical Trials

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Start date: June 15, 2020
Phase: Phase 1
Study type: Interventional

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive - Copanlisib IV: day 1, 8, 15 every 28 days - Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only - Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)

NCT ID: NCT04431089 Recruiting - Clinical trials for Marginal Zone Lymphoma(MZL)

Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma

Start date: May 9, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory follicular (FL) or marginal one (MZL) lymphoma.

NCT ID: NCT04429438 Recruiting - Clinical trials for B Cell Lymphoma (BCL)

Multi-CAR-T Cells Targeting B Cell Lymphomas

Start date: June 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and consolidation treatment for patients with highly resistant B cell lymphomas, including primary mediastinal B cell lymphoma (PMBCL) and BCL involving central nervous system (CNS-BCL). Clinical response and development of a simplified and standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.